Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOGF

Primary Symbol: C.ACOG

Healthcare Biotechnology

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

Add To Watchlist

CSE:ACOG - Post Discussion

Alpha Cognition Inc > The Power Play by The Market Herald Releases New Interviews

View:

Post by Betteryear2 on Dec 07, 2021 4:21pm

The Power Play by The Market Herald Releases New Interviews

(Sponsored)

Alpha Cognition (ACOG) has announced the functional data from their ALPHA-1062 intranasal Traumatic Brain Injury (TBI) program. Administering ALPHA-1062 reduced the extent of the functional deficit and improved functional recovery of TBI animals compared to untreated animals. The preclinical results, combined with clinical data demonstrating the safety and tolerability of ALPHA-1062, support its continued development for the treatment of TBI. ALPHA-1062 demonstrated improved motor and sensory recovery. Michael McFadden, CEO of Alpha Cognition, sat down with Caroline Egan to discuss the results of the study and what lies ahead.

For the full interview with Michael McFadden and to learn more about Alpha Cognition's pre-clinical results, click here.